BRWA
DNLI icon

B. Riley Wealth Advisors’s Denali Therapeutics DNLI Stock Holding History

B. Riley Wealth Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$332K Buy
12,813
+600
+5% +$12.3K 0.02% 593
2026
Q1 		$221K Buy
+12,213
New +$243K 0.01% 685

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

B. Riley Wealth Advisors's DNLI Position: Q2 2026 in Review

B. Riley Wealth Advisors increased its Denali Therapeutics (DNLI) stake by 4.9% in Q2 2026, buying an estimated $12.3K and bringing the position to 12,813 shares worth $332K. The position accounts for 0.02% of the portfolio, ranked #593.

B. Riley Wealth Advisors first reported a position in DNLI in Q1 2026 and has held it in 2 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • B. Riley Wealth Advisors held 12,813 shares of Denali Therapeutics worth $332K as of Q2 2026.
  • B. Riley Wealth Advisors bought 600 Denali Therapeutics shares in Q2 2026, an estimated $12.3K.
  • Denali Therapeutics made up 0.02% of B. Riley Wealth Advisors's portfolio in Q2 2026, its #593 holding.
  • B. Riley Wealth Advisors first reported a position in Denali Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on B. Riley Wealth Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.